课题基金 / 基金详情

PHASE I AND PHASE II CLINICAL STUDIES WITH LHRH ANTAGONIST

PHASE I AND PHASE II CLINICAL STUDIES WITH LHRH ANTAGONIST
LHRH 拮抗剂的 I 期和 II 期临床研究
批准号：
3886208
负责人：
RONALD S SWERDLOFF
金额：
$0.0万
依托单位：
LOS ANGELES COUNTY HARBOR-UCLA MED CTR
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3886208
关键词：
clinical trials family planning follicle stimulating hormone human subject human therapy evaluation inhibitor /antagonist injection /infusion luteinizing hormone male spermatogenesis inhibitor testosterone

项目摘要

项目成果

RONALD S SWERDLOFF的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
To establish dose response and duration of action on LH, FSH and testosterone levels after a single subcutaneous injection. The effect of 3 dose levels of LHRH antagonist given either intermittently or continuously will be studied to establish the minimal effective dose for LH and FSH suppression. To evaluate the combination of LH suppression and testosterone replacement as a method of male contraception.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE II CLINICAL STUDIES WITH LHRH AGONISTS
OLIGOSPERMIA--CONTROLLED COMPARISON OF TWO ANTI-ESTROGENS
TOLERANCE AND SAFETY OF TRANSDERMAL TESTERONE
OLIGOSPERMIA--CONTROLLED COMPARISON OF TWO ANTI-ESTROGENS
海外基金